HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.

AbstractOBJECTIVES:
Myocardial fibrosis in experimental aortic regurgitation (AR) features abnormal fibronectin with normal collagen content, but the relevant degradative processes have not been assessed.
METHODS:
To elucidate these degradative processes, mRNA (Northern) and protein levels (Western) of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), as well as MMP activity (zymography), were measured in cardiac fibroblasts (CF) from New Zealand white rabbits with experimental AR paired with normals (NL). Collagen and fibronectin were quantified by immunohistochemical staining.
RESULTS:
In AR CF versus NL CF, MMP-2 and -14 mRNA and protein were increased (both p < 0.005), while TIMPs 1-3 were slightly decreased (p < 0.05-0.005; TIMP-4 undetectable). Gelatinase activity in AR CF was 1.7 times that in NL CF (p < 0.005); fibronectinase activity was unaffected. The Jun N-terminal kinase (JNK) inhibitor SP600125 suppressed MMP-2 protein (0.4-fold, p < 0.05) and mRNA (0.7-fold, p < 0.005) in AR CF; MMP-2 levels in NL CF were unaffected. AR MMP-9 mRNA, protein and activity were low and indistinguishable from NL. In left ventricular tissue, fibronectin was increased 1.9-fold (AR vs. NL, p < 0.05). Total AR collagen was indistinguishable from NL, but the collagen III to collagen I isoform ratio decreased (0.4-fold, p < 0.05).
CONCLUSIONS:
Collagen is relatively deficient in AR fibrosis, due at least in part to upregulated MMPs and downregulated TIMPs; fibronectinase is unaltered. JNK-dependent regulation may stimulate both MMP-2 and fibronectin expression in AR, providing a potential therapeutic target.
AuthorsSharada L Truter, Daniel F Catanzaro, Phyllis G Supino, Anuj Gupta, John Carter, Edmund M Herrold, Themy F Dumlao, Jeffrey S Borer
JournalCardiology (Cardiology) Vol. 113 Issue 3 Pg. 161-8 ( 2009) ISSN: 1421-9751 [Electronic] Switzerland
PMID19129699 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright (c) 2009 S. Karger AG, Basel.
Chemical References
  • Collagen Type I
  • Collagen Type III
  • Extracellular Matrix Proteins
  • Tissue Inhibitor of Metalloproteinase-1
  • Tissue Inhibitor of Metalloproteinase-3
  • Tissue Inhibitor of Metalloproteinases
  • Tissue Inhibitor of Metalloproteinase-2
  • Fibrinogen
  • Matrix Metalloproteinases
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9
  • Matrix Metalloproteinase 14
Topics
  • Animals
  • Aortic Valve Insufficiency (metabolism, pathology, physiopathology)
  • Cells, Cultured
  • Collagen Type I (metabolism)
  • Collagen Type III (metabolism)
  • Extracellular Matrix Proteins (metabolism)
  • Fibrinogen (metabolism)
  • Fibrosis
  • Gene Expression (physiology)
  • Matrix Metalloproteinase 14 (genetics, metabolism)
  • Matrix Metalloproteinase 2 (genetics, metabolism)
  • Matrix Metalloproteinase 9 (genetics, metabolism)
  • Matrix Metalloproteinases (genetics, metabolism)
  • Myocytes, Cardiac (cytology, physiology)
  • Rabbits
  • Signal Transduction (physiology)
  • Tissue Inhibitor of Metalloproteinase-1 (genetics, metabolism)
  • Tissue Inhibitor of Metalloproteinase-2 (genetics, metabolism)
  • Tissue Inhibitor of Metalloproteinase-3 (genetics, metabolism)
  • Tissue Inhibitor of Metalloproteinases (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: